IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter and IN.PACT 018 Paclitax
Medtronic, Inc. · Decision date Jan 30, 2026
What did the FDA approve?
FDA records P140010/S091 as a supplement to PMA P140010, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Jan 30, 2026.
FDA approval order statement
a visual system with a reticulate as a manufacturing aid during the catheter subassembly welding manufacturing step to aid in ensuring proper overlap between two of the device components
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 30, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P140010/S091
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- ONU
- Decision code
- APPR
- Decision date
- Jan 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-Eluting Peripheral Transluminal Angioplasty Catheter.
- Applicant
- Medtronic, Inc.
- Product code
- ONU
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P140010. Subsequent supplements may change the device or its indications.
FDA decision timeline
P140010 · Original PMA
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter and IN.PACT 018 Paclitax
P140010/S091 received
Application receipt date recorded by FDA.
P140010/S097 · Related supplement
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
P140010/S099 · Related supplement
IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
P140010/S100 · Related supplement
IN.PACT Admiral Paclitaxelcoated PTA Balloon Catheter; IN.PACT 018 Paclitaxel-coated PTA Balloon Catheter
P140010/S091 · FDA decision
135 Review Track For 30-Day Notice
P140010/S101 · Related supplement
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
P140010/S098 · Related supplement
IN.PACT 018 Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter
P140010/S102 · Related supplement
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter; IN.PACT 018 Paclitaxel-Coated
P140010/S103 · Related supplement
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
P140010/S104 · Related supplement
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter; IN.PACT 018 Paclitaxel-Coated
P140010/S105 · Related supplement
IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PT A) Balloon Catheter
P140010/S106 · Related supplement
IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
Timeline entries are records held by MedtechLedger for P140010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Dec 30, 2014 | FDA | |
| Medtronic, Inc. | PMA supplement | Aug 12, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Aug 12, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Sep 16, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Feb 13, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Mar 6, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Apr 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 1, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 21, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 28, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Sep 24, 2026 | FDA |
Explore the linked device profile
Other records with product code ONU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Ranger Paclitaxel-Coated Balloon CatheterP190019/S043 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 4, 2026 | FDA |
Lutonix 035 Drug Coated Balloon CatheterP130024/S045 | Lutonix | PMA supplement | Jul 9, 2026 | FDA |
Ranger Paclitaxel-Coated PTA Balloon CatheterP190019/S040 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | May 1, 2026 | FDA |
RANGER Paclitaxel-Coated PTA Balloon CatheterP190019/S042 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Apr 24, 2026 | FDA |
| The Spectranetics Corp. | PMA supplement | Mar 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P140010/S091
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
